andione1983
Danger Will Robinson, Danger
- Joined
- 2 February 2009
- Posts
- 41
- Reactions
- 0
Whats the go with this company no new flash or anything down 70% today?From .021 down to .009c a share. Wondering if you think its worth a risk to jump in with 1K worth?
"Medical Therapies Limited is a pharmaceutical company engaged in the development and commercialization of products for the treatment and diagnosis of certain conditions, including acute myocardial infraction, brain ischemia, cancers and inflammatory diseases. The Company's lead drug Cuprindo is a copper complex of Indomethacin, a generic non-steroidal, anti-inflammatory drug. Its core technology enables non-steroidal, anti-inflammatory compounds (NSAID'S) to be formulated with metals in a way that may reduce their toxicity. The Company's products under development include Cuprindo topical for acute cholecystitis; Cuprindo topical for distal proctitis; Cuprindo topical for the inflammation of the gallbladder, and Cuprindo oral for acute vascular inflammation. In January 2008, Cuprindo reached early clinical development. In a safety study of a small number of healthy volunteers, it proved to have no significant adverse effects. " (from Google Finance)
"Medical Therapies Limited is a pharmaceutical company engaged in the development and commercialization of products for the treatment and diagnosis of certain conditions, including acute myocardial infraction, brain ischemia, cancers and inflammatory diseases. The Company's lead drug Cuprindo is a copper complex of Indomethacin, a generic non-steroidal, anti-inflammatory drug. Its core technology enables non-steroidal, anti-inflammatory compounds (NSAID'S) to be formulated with metals in a way that may reduce their toxicity. The Company's products under development include Cuprindo topical for acute cholecystitis; Cuprindo topical for distal proctitis; Cuprindo topical for the inflammation of the gallbladder, and Cuprindo oral for acute vascular inflammation. In January 2008, Cuprindo reached early clinical development. In a safety study of a small number of healthy volunteers, it proved to have no significant adverse effects. " (from Google Finance)